The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia
Corresponding Author
Chaitra Ujjani
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Correspondence
Chaitra Ujjani, 825 Eastlake Ave, Seattle, WA, 98109, USA.
Email: [email protected]
Search for more papers by this authorMazyar Shadman
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorRyan C. Lynch
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorPhilip A. Stevenson
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorCaitlin Grainger
University of Washington, Seattle, Washington, USA
Search for more papers by this authorJoshua A. Hill
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorMeei-Li Huang
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorLeslie Nielsen
University of Washington, Seattle, Washington, USA
Search for more papers by this authorChristina Poh
University of Washington, Seattle, Washington, USA
Search for more papers by this authorTyler Sorensen
University of Washington, Seattle, Washington, USA
Search for more papers by this authorAjay K. Gopal
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorEdus H. Warren
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorBrian G. Till
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorDaria Gausman
University of Washington, Seattle, Washington, USA
Search for more papers by this authorStephen D. Smith
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorTed Gooley
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorAlex Greninger
University of Washington, Seattle, Washington, USA
Search for more papers by this authorCorresponding Author
Chaitra Ujjani
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Correspondence
Chaitra Ujjani, 825 Eastlake Ave, Seattle, WA, 98109, USA.
Email: [email protected]
Search for more papers by this authorMazyar Shadman
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorRyan C. Lynch
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorPhilip A. Stevenson
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorCaitlin Grainger
University of Washington, Seattle, Washington, USA
Search for more papers by this authorJoshua A. Hill
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorMeei-Li Huang
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorLeslie Nielsen
University of Washington, Seattle, Washington, USA
Search for more papers by this authorChristina Poh
University of Washington, Seattle, Washington, USA
Search for more papers by this authorTyler Sorensen
University of Washington, Seattle, Washington, USA
Search for more papers by this authorAjay K. Gopal
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorEdus H. Warren
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorBrian G. Till
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorDaria Gausman
University of Washington, Seattle, Washington, USA
Search for more papers by this authorStephen D. Smith
University of Washington, Seattle, Washington, USA
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorTed Gooley
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Search for more papers by this authorAlex Greninger
University of Washington, Seattle, Washington, USA
Search for more papers by this authorAbstract
Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion.
Supporting Information
| Filename | Description |
|---|---|
| bjh18088-sup-0001-TableS1.docxWord 2007 document , 12.4 KB |
Table S1 Performance of Roche Anti-S assay and neutralization assay |
| bjh18088-sup-0002-FigureS1.pdfPDF document, 391.8 KB |
Figure S1 Inhibition curve (neutralization activity) of patient serum samples against SARS-CoV-2 Spikedelta21-D614G pseudotyped lentiviral particles with Luciferase-IReS-ZsGreen backbone (gifts from Dr. Jesse Bloom). |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Shadman M, Ujjani C. Vaccinations in CLL: implications for COVID-19. Blood. 2021; 137(2): 144–6. https://doi.org/10.1182/blood.2020009966
- 2Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021; 137(23): 3165–73. https://doi.org/10.1182/blood.2021011568
- 3Roeker LE, Knorr DA, Pessin MS, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020; 34(11): 3047–9. https://doi.org/10.1038/s41375-020-01030-2
- 4Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021; 39(8): 1031–3. https://doi.org/10.1016/j.ccell.2021.07.012
- 5 Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry. June 2020. https://www.fda.gov/media/139638/download
- 6Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020; 383(25): 2439–50. https://doi.org/10.1056/NEJMoa2027906
- 7Chan CW, Yi X, Lenza M, et al. Analytical and clinical evaluation of the semiquantitative elecsys anti-SARS-CoV-2 spike protein receptor binding domain antibody assay on the roche cobas e602 analyzer. Am J Clin Pathol. 2022; 157(1): 109–18. https://doi.org/10.1093/ajcp/aqab092
- 8Crawford KHD, Eguia R, Dingens AS, et al. Protocol and reagents for Pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020; 12(5): 513. https://doi.org/10.3390/v12050513
- 9Bradley BT, Bryan A, Fink SL, et al. Anti-SARS-CoV-2 antibody levels measured by the AdviseDx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing immunity. J Clin Microbiol. 2021; 59(9):e0098921. https://doi.org/10.1128/JCM.00989-21
- 10Steensels D, Pierlet N, Penders J, et al. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021; 326(15): 1533–5. https://doi.org/10.1001/jama.2021.15125
- 11Sun C, Gao J, Couzens L, et al. Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncol. 2016; 2(12): 1656–7. https://doi.org/10.1001/jamaoncol.2016.2437
- 12Pleyer C, Ali MA, Cohen JI, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021; 137(2): 185–9. https://doi.org/10.1182/blood.2020008758
- 13Ujjani C, Greninger AL, Shadman M, et al. Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies. Am J Hematol. 2022; 97(2): E67–9. https://doi.org/10.1002/ajh.26418
Citing Literature
